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fact sheet

INTRODUCING CONTRACEPTIVE METHODS
IN LOW-RESOURCE SETTINGS:
NEW OPPORTUNITIES IN NIGERIA
PROJECT DESCRIPTION
In October 2013, USAID awarded the Delivering
Contraceptive Vaginal Rings project to the Population
Council to foster the introduction of two contraceptive
methods. The objectives of this project are to:
1) improve availability and affordability of a threemonth Progesterone Vaginal Ring (PVR) for
postpartum breastfeeding women, and
2) facilitate regulatory approval and introduction of a
one-year contraceptive vaginal ring containing
Nestorone® and ethinyl estradiol (NES®/EE)—a
long-acting method for non-breastfeeding women
that is in the late stages of development.

MILESTONES ACHIEVED
Continued progress was made in preparing
the New Drug Application for the
investigational NES®/EE CVR for submission
to the US Food & Drug Administration (FDA).

Findings from Acceptability and Willingness
to Pay studies were widely disseminated
at national and global levels.

NOVEMBER 2016

The PVR has been added to the World
Health Organization’s Expression of
Interest (EOI) following inclusion in
WHO’s MEC and EML.
Project partner WomanCare Global (WCG)
began compilation of the PVR dossier in
preparation for registration with Nigeria’s
regulatory body, the National Agency for Food
and Drug Administration and Control
(NAFDAC).
WCG also identified a Market
Authorization Holder (MAH) for the PVR
to ensure compliance with relevant
regulatory requirements, postregistration.
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Three-Month Progesterone Vaginal Ring
The three-month PVR, a user-initiated
contraceptive, can be used safely by postpartum
breastfeeding women to help space pregnancies.
The ring contains natural progesterone and does
not affect a woman’s ability to produce breast
milk. Each ring can be used continuously for three
months, and four rings can be used successively
the first year after childbirth. Fertility generally returns shortly
after discontinuation. The PVR is approved in eight Latin
American countries, and efforts are underway to introduce it
in more countries where contraceptive choices during
breastfeeding are limited and where prolonged lactation is
prevalent.

One-Year NES/EE Contraceptive Vaginal Ring
The one-year NES/EE CVR is a long-acting
contraceptive in the late stages of development. It
contains Nestorone® (NES), a new progestin that
has been shown to be effective in suppressing
ovulation, and ethinyl estradiol (EE), an approved,
marketed hormonal compound. Once inserted by
the woman, the NES/EE CVR is designed to be left in place for
three weeks, removed for one week to allow for a monthly
menstrual cycle, and then reinserted by the woman. The same
ring can be used for up to 13 cycles (one year), with the goal of
minimizing product cost and time spent visiting a provider or
pharmacist. Phase 3 clinical trials have been completed, as
have additional clinical and product specification studies
required by the FDA. The Population Council is preparing a New
Drug Application to submit to the FDA for regulatory review.

YEAR 4 ACTIVITIES

facilitate PVR procurement by a wider number of agencies
including UNFPA, USAID, ministries of health, and social
marketing organizations.

(OCTOBER 2016 – SEPTEMBER 2017)
2.1 Implementation research on product introduction
No activities proposed.
2.2 Register the PVR in Kenya, Malawi, Nigeria,
Senegal, and Zambia
Project partner WomanCare Global (WCG) will:

•

Results of a clinical trial conducted by the Population Council
in India in collaboration with the Indian Council of Medical
Research comparing the safety and efficacy of the PVR
versus the IUD will be finalized for inclusion in the WHO-PQ
application.

•

Project staff will continue analysis of used PVRs and
compare with data collected from acceptability studies in
each country. The secondary analysis will reveal the extent to
which women adhere to PVR use; results will inform
refinement of user instructions, including those related to
ring disposal.

Complete registration with
the Nigerian regulatory body
and continue on the pathway
toward country registration in
Kenya and Senegal.

Work closely with the
selected MAH, which will be
responsible for
pharmacovigilance of the
PVR post-registration.

2.4 Design introductory strategies for contraceptive
vaginal rings

Conduct a regulatory audit of
the PVR manufacturing plant,
a requirement of regulators
and national ministries of
health.

2.3 Technical assistance for WHO Pre-Qualification of
the PVR

•

Project staff continue to provide technical assistance to
PVR manufacturer Grünenthal in many thematic areas
including a PK study, stability testing, and validation of
analytical methods. Grünenthal will seek WHO-PQ to

Foster
partnerships
with a wide
range of
stakeholders,
implementing
partners, USAIDfunded projects,
private sector
social marketing
organizations,
professional
associations,
and reproductive
supply networks
to support
subsequent
introduction of
vaginal rings.

Advocate for
inclusion of
vaginal rings in
national EMLs,
and identify
policy and
program
opportunities for
integrating new
contraceptives
into existing
implementation
plans, providing
a unified
platform for
introduction
planning.

Convene
meetings to
develop
strategies to
introduce vaginal
rings, with an
emphasis on
identifying and
training provider
cadres from
multiple
distribution
channels within
the private and
public sectors.

KEY PROJECT CONTACTS
The Population Council will lead the proposed project activities, along with a consortium that includes WomanCare Global,
Grünenthal, and QPharma. For more information about the products or the Delivering Contraceptive Vaginal Rings project,
contact Dr. Sylvia Adebajo, Dr. John Townsend, or the USAID/Washington project management staff.
Population Council staff leading this effort in Nigeria:
• Dr. Sylvia Adebajo (sadebajo@popcouncil.org)
• Dr. Salisu Ishaku
US-based Population Council staff directing the project:
• Dr. John Townsend, Principal Director (jtownsend@popcouncil.org)
• Dr. Saumya RamaRao
• Dr. Ruth Merkatz
Office of Population and Reproductive Health, USAID/Washington project management staff:
• Dr. Judy Manning, Agreement Officer’s Representative (jmanning@usaid.gov)
• Ms. Tabitha Sripipatana, Technical Advisor (tsripipatana@usaid.gov)
• Mr. Clifton Kenon, Technical Advisor (ckenon@usaid.gov)

